The Tokyo-listed pharmaceutical firm reported total revenue of 50.65 billion yen, holding steady against the 50.64 billion yen generated in 2025. While top-line figures remained stagnant, the company effectively widened its margins, resulting in an operating profit of 3.64 billion yen, up from 2.62 billion yen a year earlier. Pretax profit also followed this upward trajectory, rising to 3.81 billion yen from 2.71 billion yen. Earnings per share rose to 107.49 yen, compared to 62.74 yen in the prior fiscal year. These results were prepared in accordance with Japanese accounting standards.
In section Market Quotes
Daito Pharmaceutical Profits Surge to 3.16 Billion Yen
Daito Pharmaceutical saw its net profit climb to 3.16 billion yen for the fiscal year ending May 31, a significant jump from the 1.91 billion yen reported in the previous period. The company’s financial performance reflects a strong bottom-line improvement despite relatively flat revenue growth over the twelve-month stretch.
Comments (0)
No comments yet. Be the first!